ReviewInflammation research : official journal of the European Histamine Research Society ... [et al.]2021
Mechanistic and physiological approaches of fecal microbiota transplantation in the management of NAFLD.
Review in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 18 citations in OpenAlex.
- Faecal microbiota transplantation and glucolipid metabolic disorders: the interventional role of gut microbiota.Frontiers in endocrinology · 2026Review
- Gut-Liver Axis: The Role of Intestinal Microbiota and Their Metabolites in the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease.Gut and liver · 2025Review
- Improving fatty liver hemorrhagic syndrome in laying hens through gut microbiota and oxylipin metabolism byAnimal nutrition (Zhongguo xu mu shou yi xue hui) · 2025Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): the interplay of gut microbiome, insulin resistance, and diabetes.Frontiers in medicine · 2025Review
- A Review on the Protecting Effects and Molecular Mechanisms of Berries Against a Silent Public Health Concern: Non-Alcoholic Fatty Liver Disease.Antioxidants (Basel, Switzerland) · 2024Review
- Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review.Internal and emergency medicine · 2024Review
- Role of fecal microbiota transplant in management of hepatic encephalopathy: Current trends and future directions.World journal of hepatology · 2024Review
- Gut microbiota and Parkinson's disease: potential links and the role of fecal microbiota transplantation.Frontiers in aging neuroscience · 2024Review
- Intestinal Barrier Function in the Pathogenesis of Nonalcoholic Fatty Liver Disease.Journal of clinical and translational hepatology · 2023Review
- Geniposide plus chlorogenic acid reverses non-alcoholic steatohepatitisFrontiers in pharmacology · 2023Article
- Role of intestinal flora in primary sclerosing cholangitis and its potential therapeutic value.World journal of gastroenterology · 2022Review
- Nutrigenomics and Nutrigenetics Research in New Zealand, and Its Relevance and Application to Gastrointestinal Health.Nutrients · 2022Review
- The Role of Gut-Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC.Biomedicines · 2022Review
- Gut Microbiota and Liver Regeneration: A Synthesis of Evidence on Structural Changes and Physiological Mechanisms.Journal of clinical and experimental hepatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a multifaceted disease allied with various metabolic disorders, obesity and dysbiosis. Gut microbiota plays an influential role in the pathogenesis of NAFLD and other metabolic disorders. However, recent scientific upsurge emphasizes on the utility of beneficial gut microbiota and bacteriotherapy in the management of NAFLD. Fecal microbiota transplantation (FMT) is the contemporary therapeutic approach with state-of-the-art methods for the treatment of NAFLD. Other potential therapies include probiotics and prebiotics supplements which are based on alteration of gut microbes to treat NAFLD. In this review, our major focus is on the pathological association of gut microbiota with progression of NAFLD, historical aspects and recent advances in FMT with possible intervention to combat NAFLD and its associated metabolic dysfunctions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.